Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
Earnings Data
Report Date
Aug 11, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.03Last Year’s EPS
-0.48Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 32.13%
|Next Earnings Date:Aug 11, 2025
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for Delcath Systems, with strong revenue growth, an increase in active treatment centers, and positive financial metrics highlighting the quarter. However, challenges with European reimbursement and rising expenses tempered the overall sentiment.Company Guidance
During the Delcath Systems' First Quarter 2025 Earnings Call, the company reported significant financial and operational achievements. They announced a combined revenue of $19.8 million, with HEPZATO sales contributing $18 million in the U.S. and CHEMOSAT sales adding $1.8 million in Europe. The company ended the quarter with 19 active treating centers in the U.S., up from 17, and a strong financial position with a net income of $1.1 million and positive cash flow from operations of $2.2 million. Delcath's adjusted EBITDA was reported at $7.6 million, and they held $59 million in cash and investments with no debt. Looking ahead, Delcath aims to have 30 active centers by year-end and is actively expanding its reach by increasing its sales territories from four to six, each supported by a specialized team. The company is also advancing clinical trials for liver-dominant metastatic colorectal and breast cancer, with patient enrollment expected to begin later in 2025. These efforts are part of Delcath's broader strategy to expand the applications of its liver treatment platform beyond metastatic uveal melanoma.Strong Revenue Growth
Combined revenue for HEPZATO and CHEMOSAT reached $19.8 million in Q1 2025, with HEPZATO contributing $18 million and CHEMOSAT contributing $1.8 million. This represents significant growth compared to the previous year.
Increased Active Centers
The company ended Q1 2025 with 17 treating sites and opened an additional two centers, bringing the total to 19 active centers in the U.S., with 10 more centers pending activation.
Positive Financial Metrics
Delcath Systems reported positive cash from operations of $2.2 million, net income of $1.1 million, and a positive adjusted EBITDA of $7.6 million for Q1 2025. The company also ended the quarter with no debt and $59 million in cash and investments.
European Market Growth
The European market for CHEMOSAT grew by 29% over the prior quarter to $1.8 million, despite reimbursement challenges.
Pipeline Expansion
FDA clearance was received for Phase II trials in metastatic colorectal and breast cancer, with plans to start by the end of 2025.
DCTH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DCTH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $11.61 | $14.36 | +23.69% |
Mar 06, 2025 | $13.43 | $13.22 | -1.56% |
Nov 08, 2024 | $10.94 | $11.06 | +1.10% |
Aug 05, 2024 | $8.32 | $7.91 | -4.93% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Delcath Systems (DCTH) report earnings?
Delcath Systems (DCTH) is schdueled to report earning on Aug 11, 2025, TBA Not Confirmed.
What is Delcath Systems (DCTH) earnings time?
Delcath Systems (DCTH) earnings time is at Aug 11, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DCTH EPS forecast?
DCTH EPS forecast for the fiscal quarter 2025 (Q2) is 0.03.